Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Emily Singer

A View from Emily Singer

Dope Test Before Drug Is Tested in Humans

Scientists are creating anti-doping tests earlier and earlier in drug development.

  • January 8, 2009

Some athletes and trainers are tuned in to the drug-development pipeline, looking for the next big doping agent: experimental drugs that can boost strength and endurance but are new enough to slip under the screening radar. One scientist I spoke to for a previous piece on doping said that he still gets flooded with calls from athletes years after publishing details of a promising advance in drug development for muscular dystrophy.

In an effort to combat the abuse of new compounds before it starts, anti-doping agencies have begun working with drug companies to develop screening tests before drugs are even on the market. In last year’s Tour de France, the World Anti-Doping Agency caught several cyclists using a longer-lasting form of the endurance booster EPO (erythropoietin), called CERA. Soon after the athletes were caught, it was revealed that the agency had been working with Swiss drugmaker Roche to develop a test to detect CERA while the drug was still being tested by the U.S. pharmaceutical company Amgen.

Now German scientists announce that they have developed a test for a class of compounds called benzothiazepines, which are being developed for the treatment of heart abnormalities and have been shown to boost endurance in mice. According to a press release from Drug Testing and Analysis, the journal publishing the research,

These compounds stabilize protein channels that would otherwise “leak” calcium from muscle cells during strenuous exercise. Calcium is needed for muscle contraction and this “leaking” effect weakens the contractions and is a causal factor in muscle fatigue.

While the drugs have not yet been tested in humans, researchers say that they carry a high potential for abuse because they are easy to make.

“As soon as these drugs enter human clinical trials, there is a huge potential for them to be misused in sports. This preventive research lets us prepare before these compounds are officially launched,” says Mario Thevis, Director of the Center for Preventive Doping Research at the German Sport University of Cologne, Germany, who led the research.

The study characterises the compounds according to their weight and molecular structure. This gives the researchers a molecular “fingerprint” by which to identify the compounds. Thevis and colleagues show that, using high resolution mass spectrometry, JTV-519 and S-107 can be detected in spiked urine at concentrations as low as 0.1 nanograms per millilitre.

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.

Subscribe today

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe and become an Insider.
  • Insider Premium {! insider.prices.premium !}*

    {! insider.display.menuOptionsLabel !}

    Our award winning magazine, unlimited access to our story archive, special discounts to MIT Technology Review Events, and exclusive content.

    See details+

    What's Included

    Bimonthly magazine delivery and unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

    First Look: exclusive early access to important stories, before they’re available to anyone else

    Insider Conversations: listen in on in-depth calls between our editors and today’s thought leaders

  • Insider Plus {! insider.prices.plus !}* Best Value

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus ad-free web experience, select discounts to partner offerings and MIT Technology Review events

    See details+

    What's Included

    Bimonthly magazine delivery and unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning magazine and daily delivery of The Download, our newsletter of what’s important in technology and innovation.

    See details+

    What's Included

    Bimonthly magazine delivery and unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.